Press Releases

Date Title
June 23, 2020
Outlook Therapeutics Announces $11.2 Million Financings Priced At-The-Market Under Nasdaq Rules
MONMOUTH JUNCTION, N.J. , June 23, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“the Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that
June 17, 2020
Outlook Therapeutics Provides Clinical Update on ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
Lead product candidate ONS-5010 / LYTENAVA TM   (bevacizumab-vikg)   has potential to be first FDA-approved ophthalmic formulation of bevacizumab for use in multiple retinal indications   Topline results from NORSE 1, the Company’s first registration clinical trial evaluating ONS-5010 and providing
June 11, 2020
Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
MONMOUTH JUNCTION, N.J. , June 11, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced today that
June 9, 2020
Outlook Therapeutics to Present at the Virtual Investor Fireside Chat Series
Live moderated video webcast discussion with President, CEO and CFO Lawrence Kenyon, on Wednesday, June 17th at 2:00 PM ET, immediately followed by an interactive Q&A session MONMOUTH JUNCTION, N.J. , June 09, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.
June 3, 2020
Outlook Therapeutics Announces Closing of $16.0 Million Private Placement
MONMOUTH JUNCTION, N.J. , June 03, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the
May 26, 2020
Outlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
Strategic investment at a premium enhances Company’s ongoing development activities of ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab to treat wet AMD, toward FDA approval   Syntone and Outlook to form joint venture to develop and commercialize
May 15, 2020
Outlook Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2020 and Provides Corporate Update
Company remains on track to report topline data results from NORSE 1, its first registration clinical trial evaluating ONS-5010, an investigational ophthalmic formulation of bevacizumab to treat wet AMD, in August 2020   Enrollment in NORSE 2 registration clinical trial remains ongoing and is
April 21, 2020
Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors
Internationally renowned ophthalmologist, Gerd Auffarth , MD, ranked as one of the “100 most influential personalities in ophthalmology worldwide" in the 2020 Power List published by The Ophthalmologist  magazine Julian Gangolli , former President of the North American Pharmaceutical division of
April 15, 2020
Outlook Therapeutics to Present at the April 2020 Virtual Investor Summit
Presentation with live audio webcast on Wednesday, April 22 at 10:30 AM ET, immediately followed by an interactive Q&A session CRANBURY, N.J. , April 15, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to
April 14, 2020
Outlook Therapeutics Provides COVID-19 Impact Update on Ongoing Clinical Trials NORSE 1 and NORSE 2
Company reports no anticipated COVID-19 impact on NORSE 1, its first registration clinical trial evaluating ONS-5010, an investigational ophthalmic formulation of bevacizumab, to treat wet AMD   Risk mitigation strategies being developed for possible one- to three-month delay related to COVID-19
Displaying 11 - 20 of 96